Instructions for Vagiferon
Active ingredients Vagiferon:
- Metronidazole: 250 mg
- Fluconazole: 150 mg
- interferon alpha: 50000 МЕ
Metronidazole - antiprotozoal and antibacterial drug
The composition of vaginal suppositories Vagiferon:
1 suppository suppository contains:
Active ingredients Vagiferon: Interferon alpha-2b human recombinant at least 50,000 IU.
Metronidazole 250 mg and fluconazole 150 mg.
Excipients: boric acid 400 mg, disodium edetate 2 mg,
base up to 2 g:
macrogol 1500 - 92%
macrogol 400 - 8%.
Indications for use vaginal suppositories Vagiferon:
- bacterial vaginosis
- bacterial (nonspecific) vaginitis
- vaginitis caused by mixed infection (Trichomonas, gardenarella
- yeast-like mushrooms
- herpes simplex virus types 1 and 2
- mycoplasma, ureaplasma
Pharmacodynamics of Vagiferon:
It belongs to the number of combined drugs for intravaginal use. It has antiviral, immunomodulatory, anti-inflammatory, antifungal, antimicrobial and antiprotozoal (trichomonacid) effect.
Properties of the active components of the drug: Metronidazole, Fluconazole: is a derivative of 5-nitroimidazole; it has antiprotozoal and antibacterial effects. The mechanism of action of the drug lies in the biochemical reduction of the 5-nitro group of metronidazole by intracellular transport proteins of protozoa and anaerobic microorganisms. Shows activity against Gardnerella vaginalis, Trichomonas vaginalis, as well as gram-negative anaerobes Bacteroides spp.,
Fusobacterium spp. and some gram-positive anaerobes (sensitive strains - Peptococcus niger, Eubacterium spp., Peptostreptococcus spp., Clostridium spp., Mobiluncus spp.). Facultative anaerobes and aerobic microorganisms are not sensitive to the active Metronidazole; fluconazole: has a highly specific fungicidal (antifungal) effect. Shows activity in mycoses, including Candida spp. (including generalized forms of candidiasis against the background of immunosuppression), Coccidioides immitis and Cryptococcus neoformans, Blastoyces dermatitidis, Microsporum spp. When administered intravaginally, it is more active against Candida albicans, to a lesser extent - Candida glabrata; interferon alpha-2b: has a pronounced immunomodulatory and antiviral effect.
Pharmokinetics Vagiferon:
After intravaginal administration of suppositories, the bioavailability of Metronidazole is 20% compared with oral administration. After intravaginal administration, it undergoes systemic absorption (about 56%). Substances are metabolized in the liver by hydroxylation, oxidation and glucuronidation. Main metabolite activity
(2-oxyMetronidazole) accounts for 30% of the activity of the parent compound. The half-life of substances is six to twelve hours. It is excreted by 50-70% (about 20% in unchanged form) through the kidneys.
Contraindications Vagiferon:
Pregnancy and lactation.
Age under 18.
individual and intolerance to the components of the drug, as well as nitroimidazole derivatives.
The course of admission Vagiferon, intravaginally.
1 vaginal suppository in the evening (before bedtime), for 10 days.
Special instructions for drug treatment Vagiferon:
During the period of treatment with vaginal suppositories, it is recommended to refrain from sexual intercourse. In the case of using the drug together with Metronidazole for oral administration, especially with a repeated course, it is necessary to control the picture of peripheral blood (danger of leukopenia).
During the treatment period, Fluconazole, ethanol intake is contraindicated (disulfiram-like reactions may develop: abdominal pain of a spastic nature, nausea, vomiting, headache, sudden "rush" of blood to the face). You should not prescribe Metronidazole to patients who have taken disulfiram within the past 2 weeks. Influence on the ability to drive vehicles and control mechanisms The drug Vagiferon does not affect the ability to drive vehicles and engage in other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions.
